Placebo - SC

DRUG11 trials

Sponsors

Eli Lilly and Company

Conditions

DyslipidemiasHealthyOsteoarthritis, KneePsoriasis

Phase 1

A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women

CompletedNCT01742091

Eli Lilly and CompanyHealthy

Start: 2009-09-30End: 2010-03-31Updated: 2018-07-18

A Study of Mirikizumab (LY3074828) in Healthy Participants

CompletedNCT02568423

Eli Lilly and CompanyHealthy

Start: 2015-12-02End: 2018-10-24Updated: 2024-02-08

A Study of LY3361237 in Healthy Participants

CompletedNCT03695198

Eli Lilly and CompanyHealthy

Start: 2018-10-26End: 2019-08-29Updated: 2019-09-04

A Study of LY3475766 in Healthy Participants

CompletedNCT04052594

Eli Lilly and CompanyDyslipidemias

Start: 2019-09-03End: 2021-03-31Updated: 2021-04-28

A Study of Mirikizumab in Healthy Chinese Participants

CompletedNCT04137380

Eli Lilly and CompanyHealthy

Start: 2019-12-04End: 2020-12-11Updated: 2024-01-26

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

TerminatedNCT04152382

Eli Lilly and CompanyPsoriasis

Start: 2019-11-20End: 2022-02-09Updated: 2022-03-15

A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants

CompletedNCT04178733

Eli Lilly and CompanyHealthy

Start: 2020-01-10End: 2020-05-11Updated: 2025-01-14

A Study of LY3478006 in Healthy Participants

TerminatedNCT04230122

Eli Lilly and CompanyHealthy

Start: 2020-02-17End: 2020-06-04Updated: 2021-12-06

A Study of LY3461767 in Healthy Participants

CompletedNCT04352114

Eli Lilly and CompanyHealthy

Start: 2020-06-15End: 2021-01-13Updated: 2021-02-05

A Study of Ramucirumab (LY3009806) in Healthy Participants

CompletedNCT04495478

Eli Lilly and CompanyHealthy

Start: 2020-07-30End: 2021-05-09Updated: 2023-02-14

Phase 2

A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain

TerminatedNCT02192190

Eli Lilly and CompanyOsteoarthritis, Knee

Start: 2014-07-31End: 2015-06-30Updated: 2019-09-10

Related Papers

Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial

Nature Medicine2025-07-1011 citations

S1108 Safety, Tolerability, and Pharmacokinetics of Mirikizumab in Chinese Healthy Subjects: Results From a Phase 1 Study

The American Journal of Gastroenterology2023-10-01

Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.

2023-08-2317 citations

CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial.

2018-09-1845 citations